Estonian Genome Center: Science Center
From January 1st, 2018 University if Tartu has a new Institute of Genomics, which was established by merging Estonian Genome Center and Estonian Biocentre (joined University of Tartu January 1st, 2018). The head of Estonian Genome Center: Science Center is vice director, senior research fellow Dr. Tõnu Esko, tonu.esko [ät] ut.ee
Research group of pharmacogenetics
Despite recent advances in pharmacogenomic research, interindividual variability in drug metabolism and sensitivity for drug toxicity persists as a major problem for drug treatment. Recent research has highlighted the large extent of rare variant in genes with importance for drug metabolism. The aim of this work is to discover and investigate the effect of common and rare genetic variants related to suboptimal drug metabolism and adverse drug reactions (ADRs) in the Estonian and other European populations. This will be achieved by using genome sequences of 5000 and genotype data of 50,000 individuals combined with extensive health records regarding drug prescriptions and ADR diagnoses. The identified gene-ADR associations will be tested using functional studies. The results will serve as a basis for variants that can be included for preemptive pharmacogenomic testing, which could ultimately reduce the health and economic burden of low drug efficacy and unnecessary side effects caused by genetic variants.
The research group of pharmacogenetics is lead by senior researcher Dr. Lili Milani, lili.milani [ät] ut.ee
Research group of metabolomics and systems
Studies the interactios between the genome and metabolome with regard to human diseases. This includes work with metabolomics data sets collected with NMR and mass-spectrometry. We search for associations between genomic markers and metabolite levels as well as more complicated patterns in these data sets with the intent to understand and predict common diseases. This work requires creating new bioinformatics algorithms, scripts and tools (C++, Phython) as well as conducting high pergormance cluster computations.
The research group of metabolomics and systems is lead by senior researcher Dr. Toomas Haller, toomas.haller [ät] ut.ee
Research group of mRNA
It is known that the genome apparently healthy individuals acutally harbors dozens of gene-disrupting variants (predicted to results in loss of function at the protein level). On the other hand, many phenotypic traits show inconsistent inheritance patterns due to penetrance and expressivity. The very first readout of genomic information is RNA, where celss have evolved several quality control mechanisms to minimize the impact of potentially harmful mutations. Our aim is to understand how mRNA regulation contributes to the buffering of such deleterious genetic variants.
The research group of mRNA is lead by senior researcher Dr. Tarmo Annilo, tarmo.annilo [ät] ut.ee
Research group of microbiome
The human intestinal tract is colonized by thousands of different species of microorganisms, collectively called the microbiota. The gut microbiome (collection of all microbial genes) encodes much more genes than the human genome and provides us with numerous complementary functions. The microbioal community has a critical role in many aspects of health, including immunit and metabolism. Our group addresses questions about the relationships between microbiome and human host, where we currently focus on two major ares: 1) we explore the host-microbiome interactions in development of type 2 diabetes and 2) elucidate the direct and indirect mechanisms through which the human microbiome shapes the efficacy and toxicity of commonly used drugs.
The research group of microbiome is lead by senior researcher Dr. Elin Org, elin.org [ät] ut.ee